Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study

NCT02884479 is registered in ClinicalTrials.gov with SciClone Pharmaceuticals International (Cayman) Development Limited as lead sponsor.

NCT NCT02884479
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02884479 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study
Lead sponsor
SciClone Pharmaceuticals International (Cayman) Development Limited
Phase
Phase 1/2
Overall status
Unknown status
Start date
August 31, 2016
Completion date
March 31, 2019
Enrollment
75 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, non-small cell lung cancer